Generative AI for Nutraceutical Regulatory Affairs: Automating Dossier Preparation and Claims Review

Generative artificial intelligence (generative AI), and the large language models (LLMs) behind it, is entering nutraceutical regulatory affairs as a drafting and review assistant, not an autonomous decision-maker. In dossier work (European Union novel food applications, United States new dietary ingredient (NDI) notifications, and technical safety dossiers), it can accelerate literature retrieval, first-draft assembly, formatting to a required structure, and cross-document consistency checks.

In claims work, it can screen structure/function and health-claim wording against the line that separates permitted claims from prohibited disease claims, and help map a claim to its evidence.

The recurring constraints are consistent across every use case:

• Accuracy: LLMs predict plausible text and do not evaluate truth, so they can fabricate citations, studies, or regulatory statuses (a failure commonly called hallucination).
• Validation: any tool used in a regulated (good practice, or GxP) workflow falls under computer system validation and data-integrity expectations, with no carve-out for AI.
• Accountability: the company, not the tool, owns the accuracy of every submitted document, so a qualified human must review and approve AI output.

For regulatory teams, the practical 2026 model is human-led and AI-assisted: retrieval-grounded drafting, strict source traceability, and a documented review step before anything reaches a regulator. This article covers the use cases, then the regulatory acceptance, validation, and data-governance guardrails.

Content overview:

• What Generative AI Means in Nutraceutical Regulatory Affairs
• Use Case: Dossier Preparation and Drafting
• Use Case: Claims Substantiation and Claims Review
• Use Case: Regulatory Intelligence and Horizon Scanning
• Use Case: Safety and Pharmacovigilance Literature Screening
• Use Case: Label and Advertising Compliance Checks
• How Regulators View AI in Submissions
• The Validation and Accuracy Problem
• Data Governance and Confidentiality
• The Solution Landscape, by Category
• Limitations and What Stays Human
• Frequently Asked Questions
• Key Takeaways
• Sources

What Generative AI Means in Nutraceutical Regulatory Affairs

Regulatory affairs in the dietary supplement and functional food sector is document-intensive and language-intensive. Teams assemble safety dossiers, notify authorities of new ingredients and claims, monitor changing rules across markets, and police the wording of every on-pack and marketing statement. These are exactly the tasks where LLMs, which generate and transform text, appear useful.

Generative AI differs from the predictive and modelling AI already reshaping the sector. Tools that design formulations or simulate absorption are covered separately in this overview of how AI and digital twin technology are changing nutraceutical formulation, and in this survey of AI formulation tools reshaping the industry. Regulatory affairs is a distinct application: the output is not a product but a document, a claim, or a compliance judgement, and the tolerance for error is set by law rather than by formulation performance.

Two features of the domain shape everything that follows. First, nutraceutical regulation is fragmented and definitional: the category itself lacks a single legal definition, which pushes much of the regulatory burden onto precise, defensible wording. Second, the field is held to evidentiary and advertising-law standards, so an assistant that produces fluent but unsupported text is a liability rather than a shortcut. The value of generative AI here is bounded by how well it can be grounded in verified sources and constrained by human review.

See and download our infographic on Generative AI in Nutraceutical Regulatory Affairs

Use Case: Dossier Preparation and Drafting

Dossier preparation is the most frequently cited application. An EU novel food application under Regulation (EU) 2015/2283, a US NDI notification, or a national supplement registration each requires a large, structured evidence package: identity and composition, manufacturing process, specifications, proposed use levels, and a toxicological and safety narrative. The depth expected is visible in a published novel food safety assessment such as the European Food Safety Authority’s (EFSA) evaluation of cannabidiol, where data gaps alone can hold up an authorisation. Assembling one is slow, and much of the effort is retrieval, summarisation, and formatting rather than original scientific judgement.

Generative AI can plausibly reduce that effort in several ways:

• Literature retrieval and summarisation. Surfacing and condensing relevant studies, monographs, and prior opinions into structured summaries, which a scientist then checks against the primary sources.
• First-draft section assembly. Producing draft text for descriptive sections (identity, composition, manufacturing description) that follow a fixed template.
• Formatting and consistency. Mapping content into a required dossier structure, and flagging inconsistencies (for example, a specification value that differs between two sections).
• Gap analysis. Comparing a draft against a published data requirement checklist and listing what appears to be missing.

Peer-reviewed work has begun to frame LLMs as a tool for analysing food-health relationships and supporting the substantiation task that sits at the centre of this work [1]. Domain-adapted extraction methods, such as retrieval-augmented frameworks that pull dietary-supplement entities and relationships out of unstructured records, point toward more reliable, grounded assistance than a general chatbot can offer [2]. The consistent caveat in this literature is that the food and nutrition domain lacks the mature natural language processing infrastructure of biomedicine, so general-purpose models tend to underperform without domain adaptation [1].

Use Case: Claims Substantiation and Claims Review

Claims are where the regulatory stakes are highest and where generative AI is both most tempting and most dangerous. In the US, the Dietary Supplement Health and Education Act of 1994 (DSHEA) permits structure/function claims but prohibits disease claims, and the Federal Trade Commission (FTC) requires competent and reliable scientific evidence to substantiate any health benefit claim. In the EU, only health claims authorised under Regulation (EC) 1924/2006 may be used. The line between a permitted and a prohibited claim is a legal distinction, not a linguistic one.

Used carefully, generative AI can support claims work by drafting candidate structure/function wording, retrieving and organising the human studies behind a claim, and screening existing copy for language that drifts toward a disease claim. Mapping a proposed claim to its evidence base, and to the relevant authorised-claim register, is a genuine efficiency gain when the model is grounded in a curated, verified corpus.

The danger is that a general-purpose model does the opposite of what compliance requires. Because such models are trained on large volumes of internet text that include a great deal of non-compliant supplement marketing, and because they reproduce frequent language patterns rather than applying statutory categories, they can default to producing exactly the copy a compliance team must reject: implied disease claims, missing disclaimers, and, most seriously, fabricated substantiation. Reported failures include invented clinical studies and specific efficacy figures that do not exist, which is a direct consequence of a model that predicts plausible text and does not evaluate whether that text is true [3]. Every claim an AI helps draft therefore has to be traced back to a real, cited study and checked against the applicable claims framework before use. For context on how that framework varies, note that securing even a single authorised health claim typically rests on human intervention studies and regulator review.

Use Case: Regulatory Intelligence and Horizon Scanning

Keeping current with changing rules across markets is a natural fit for language models, because the task is reading and summarising large volumes of published regulatory text. Generative AI can monitor agency websites, guidance updates, and official journals, then summarise what changed and flag items relevant to a given ingredient or product portfolio. It can also compare two versions of a guidance document and highlight the substantive differences.

This is a high-value, lower-risk application than dossier drafting, because the output is an internal briefing and a human specialist validates anything that drives a decision. The country-by-country variation that makes it hard is well illustrated by the way herbal food supplement rules differ across the EU and beyond, where national implementations diverge on composition, labelling, and permitted claims. Even here, grounding matters: a summary that misstates a maximum permitted level or an authorisation status is worse than none.

Use Case: Safety and Pharmacovigilance Literature Screening

Post-market safety monitoring generates large volumes of unstructured text: adverse event reports, case narratives, and a continuous stream of new literature. Generative AI and related language models can triage this material by classifying reports, extracting suspected ingredient-event pairs, and summarising the literature on a given ingredient’s tolerability and interactions. Retrieval-augmented extraction of supplement information from clinical records is an active research direction aimed precisely at this problem [2].

The accuracy stakes are high, because a missed or misclassified safety signal has consequences beyond a single document. Published analyses of LLMs in safety contexts have found that models can repeat or elaborate on errors introduced into their inputs in a large share of cases, and that prompt-based mitigations reduce but do not eliminate the problem [4]. In practice this argues for using AI to prioritise and summarise safety information for human reviewers, not to make safety determinations, and for keeping a qualified reviewer accountable for every signal decision.

Use Case: Label and Advertising Compliance Checks

Label and advertising review is pattern-heavy: checking that mandatory statements are present, that disclaimers appear where required, that ingredient names and quantities are consistent, and that no wording implies an unauthorised effect. The volume of applicable rules is significant, as the EU framework for labelling and composition of food supplements illustrates. Generative AI can act as a first-pass screen, comparing draft artwork or marketing copy against a rules checklist and flagging likely problems for a specialist to confirm.

As with claims, the model’s suggestions are a starting point, not a verdict. A screen that catches an obvious disease claim is useful; a screen trusted to clear copy for market without human sign-off inherits every accuracy risk described below. AI narrows the reviewer’s workload; the reviewer, not the model, gives the approval.

Read our article on Regulatory Compliances for Food and Nutraceuticals in USA

How Regulators View AI in Submissions

No jurisdiction has issued dietary-supplement-specific rules on using generative AI in regulatory submissions. The relevant signals come from adjacent frameworks, and they point in a consistent direction: AI is permitted as a tool, provided its use is transparent, validated, and human-supervised.

On the US side, the most concrete signal is the US Food and Drug Administration’s (FDA) January 2025 draft guidance on using AI to support regulatory decision-making for drug and biological products. It proposes a risk-based credibility assessment: define the question the model answers, define its context of use, assess the risk if the model is wrong, and provide credibility evidence proportional to that risk [5]. The guidance addresses drugs and biologics rather than supplements, so it does not bind dietary supplement submissions, but its logic (more influence and higher stakes require more validation evidence) is the clearest indication of how the agency reasons about AI in regulatory documents. Separately, the FTC has been explicit that organisations remain responsible for the accuracy of AI-assisted output, so an AI-generated substantiation error is the company’s error.

On the EU side, food regulators have signalled openness to AI-supported dossiers on the condition of full transparency. Commentary on novel food practice indicates that EFSA-facing submissions can incorporate AI provided data sources, methods, and verification are traceable and models are validated against observed data, with human experts remaining in the loop to catch errors [6]. Layered on top is the EU Artificial Intelligence Act (Regulation (EU) 2024/1689), the first comprehensive horizontal AI law, which classifies systems by risk tier according to their intended purpose and imposes obligations such as risk management, transparency, and human oversight on higher-risk uses [7]. A regulatory-affairs assistant that drafts internal summaries sits at a very different risk level than a system making autonomous safety or compliance determinations, and the intended purpose is what drives the classification.

Table 1. How adjacent frameworks frame AI in the regulated workflow

The Validation and Accuracy Problem

The central technical obstacle is that LLMs are non-deterministic and do not assess truth. They generate statistically plausible language, which means the same prompt can yield different answers and that any answer may be confidently wrong. In a regulatory context, a fabricated citation, an invented study result, or a misstated approval status is not a cosmetic error; it is a data-integrity failure. Practitioners increasingly describe hallucination as a governance risk rather than a mere software bug, because the output is presented with apparent authority [8].

This is why validation, not model capability, is usually the binding constraint. Once a generative tool is used operationally in a GxP setting, it becomes part of the regulated environment and falls under computer system validation (CSV) expectations, including US 21 CFR Part 11 and EU Annex 11 for electronic records and signatures, with industry practice guided by frameworks such as GAMP 5 (Good Automated Manufacturing Practice). There is no AI exemption from these requirements. Two consequences follow directly:

• The model cannot sign. Electronic signatures under Part 11 are applied by an accountable person, not by a model, so the compliant pattern is human-in-the-loop review followed by human sign-off.
• Every draft is preliminary. AI output is treated as a draft to be verified against source data, and it does not bypass the normal review-and-approval workflow before entering a controlled document.

Because generative output is probabilistic, validation cannot prove absolute accuracy in the way it can for deterministic software. The workable approach is to measure performance characteristics, constrain the model with retrieval grounding, log inputs and outputs for an audit trail, and design the surrounding process so a human catches errors before they matter. Risk-based validation thinking, consistent with the FDA’s Computer Software Assurance (CSA) approach, concentrates the heaviest evidence on the uses where an error would do the most damage.

Data Governance and Confidentiality

Regulatory dossiers contain some of a company’s most sensitive material: proprietary formulations, manufacturing know-how, unpublished study data, and other confidential business information. Sending that content to a general-purpose, consumer-grade AI service raises immediate confidentiality and data-residency concerns, because inputs may be retained, processed outside a controlled jurisdiction, or reused in ways the submitter cannot audit.

The governance response mirrors any other handling of sensitive regulated data:

• Prefer deployments that keep proprietary and personal data within a controlled boundary, with contractual guarantees that inputs are not retained or reused for training.
• Restrict which document classes may be processed by which tools, and log that usage.
• Apply the same access controls, retention rules, and audit expectations that govern the rest of the regulatory record.

These concerns are not unique to regulatory affairs; the broader adoption of AI in nutrition has repeatedly surfaced the same tension between capability and data privacy and regulatory gaps. In a regulated function, unresolved data governance is a reason not to deploy, not a detail to settle later.

The Solution Landscape, by Category

The tools reaching this space fall into recognisable categories rather than a single product type. Describing them by capability is more durable than by brand, because vendors and features change quickly and naming them risks reading as endorsement.

• General-purpose assistants. Broad chat and drafting tools. Useful for low-stakes internal drafting and ideation, but poorly suited to regulator-facing work because they are ungrounded, unvalidated, and confidentiality-exposed by default.
• Retrieval-grounded regulatory intelligence. Platforms that apply generative AI on top of a curated regulatory corpus, answering questions with cited references and summarising or comparing guidance. Grounding in a verified corpus, rather than open-web text, is what reduces hallucination.
• Submission and regulatory information management systems. Established regulatory information management (RIM) and electronic Common Technical Document (eCTD) publishing tools that increasingly embed AI to draft, validate structure, and check technical compliance before dispatch.
• Vertical supplement-compliance tools. Narrower tools aimed specifically at dietary supplement innovation and compliance, which try to encode the sector’s claim rules rather than leave them to a general model. Industry bodies have begun to profile such vertical applications [9].
• Domain-adapted extraction models. Research-grade methods that extract structured supplement and safety information from unstructured text, aimed at the pharmacovigilance and evidence-synthesis tasks where general models underperform [2].

Across categories, the differentiator that matters for regulatory use is not fluency but grounding, traceability, and validation support: a tool that cites its sources, refuses to answer when it cannot, and produces an audit trail is usable in a way an ungrounded assistant is not.

Table 2. Generative AI across nutraceutical regulatory tasks

Limitations and What Stays Human

The limits of the technology define the operating model. Generative AI does not evaluate truth, cannot be the accountable signatory, underperforms in the food and nutrition domain without adaptation, and inherits the confidentiality profile of wherever it runs, and none of this is solved by a better prompt or a larger model.

What stays human is therefore substantial: the scientific judgement in a safety assessment, the legal judgement in a claim, accountability for what is submitted, and final approval on any regulator-facing document. The realistic 2026 posture is augmentation, not replacement: any deployment that assumes AI removes the specialist takes on regulatory, legal, and reputational risk the efficiency gain does not justify.

Frequently Asked Questions

Can generative AI write a novel food or NDI dossier on its own?

No. It can accelerate the retrieval, summarisation, drafting, and formatting that make up much of the work, but the scientific content must be verified against primary sources and the submission owned by a qualified person. Regulators that have signalled openness to AI-supported dossiers condition it on full transparency of data and methods and on human verification of the output.

Why is using a general-purpose chatbot risky for supplement claims?

General-purpose models predict plausible language rather than applying the legal distinction between structure/function and disease claims, which exists in statute, not in language patterns. Trained on web text that includes non-compliant supplement marketing, they can default to producing implied disease claims, omit required disclaimers, and fabricate clinical substantiation. Every AI-assisted claim must be traced to real evidence and checked against the applicable framework.

Does the FDA allow AI in regulatory submissions?

There is no dietary-supplement-specific rule. The FDA’s January 2025 draft guidance on AI credibility addresses drugs and biologics, proposing validation evidence proportional to the risk of the model’s context of use. Its risk-based logic is the clearest available signal of regulatory thinking, but it does not itself bind supplement submissions, and the company remains responsible for accuracy.

What does the EU AI Act mean for a regulatory-affairs assistant?

The EU AI Act classifies systems by risk according to intended purpose. A tool that drafts internal summaries or first drafts under human review is a much lower-risk use than a system making autonomous compliance or safety determinations. Obligations such as human oversight, transparency, and documentation scale with that risk level, so the intended use should be defined and documented deliberately.

Do AI tools used in regulated workflows need computer system validation?

Yes. Once a generative tool is used operationally in a GxP setting, it falls under computer system validation and data-integrity expectations, including 21 CFR Part 11 and EU Annex 11, with no AI exemption. Because output is non-deterministic, validation focuses on performance characteristics, retrieval grounding, audit logging, and a human review-and-sign-off step rather than on proving absolute accuracy.

What is the safest way to start using generative AI in regulatory affairs?

Begin with lower-stakes, internally facing tasks such as regulatory intelligence summaries and first-draft assembly, use tools grounded in a verified corpus that cite their sources, keep proprietary data inside a controlled boundary, and require a qualified human to verify and approve every output before it informs a decision or reaches a regulator.

Key Takeaways

Generative AI in nutraceutical regulatory affairs is a drafting and review assistant in 2026, useful for dossier assembly, claims screening, regulatory intelligence, safety literature triage, and label checks, but not an autonomous decision-maker.

The core technical risk is that LLMs generate plausible text without evaluating truth, so hallucinated citations, studies, and regulatory statuses are a governance and data-integrity problem, not a cosmetic one.

Claims work carries the highest stakes: general-purpose models can default to non-compliant supplement copy, including fabricated substantiation, because the structure/function versus disease distinction lives in law, not in language patterns.

No jurisdiction has supplement-specific AI submission rules; the FDA’s drug and biologic credibility framework, EFSA-facing transparency expectations, the FTC accountability standard, and the EU AI Act together point to permitted-but-supervised use.

Any AI used in a GxP workflow requires computer system validation under 21 CFR Part 11 and EU Annex 11, cannot be the accountable signatory, and must sit behind a documented human review step.

Data governance is a gating condition: proprietary dossier content and confidential business information should stay within a controlled boundary, and unresolved confidentiality is a reason not to deploy.

Sources

1. “Large language models and generative AI for food and nutrition: opportunities for health-claim analysis (review).” BioMedInformatics, vol. 6, art. 13, 2026. https://www.mdpi.com/2673-7426/6/2/13 (accessed 2026-07-12).

2. “RAMIE: Retrieval-Augmented Multi-task Information Extraction for Dietary Supplement Information from Clinical Records.” arXiv preprint (subsequently published in a peer-reviewed venue), 2024. https://arxiv.org/pdf/2411.15700 (accessed 2026-07-12).

3. DTC Skills. “Why Generic AI Copy Gets Supplement Brands in Trouble.” DTC Skills, 2025. https://dtcskills.com/blog/why-generic-ai-copy-gets-supplement-brands-in-trouble (accessed 2026-07-12).

4. Clinevo Technologies. “AI Governance in Pharmacovigilance.” Clinevo Technologies, 2026. https://www.clinevotech.com/blog/ai-governance-pharmacovigilance-2026/ (accessed 2026-07-12).

5. US Food and Drug Administration. “FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions.” FDA News, January 2025. https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-product-submissions (accessed 2026-07-12).

6. FoodNavigator. “How AI Gets Your Novel Food Approved Faster.” FoodNavigator (William Reed), June 30, 2025. https://www.foodnavigator.com/Article/2025/06/30/how-ai-gets-your-novel-food-approved-faster/ (accessed 2026-07-12).

7. Regulatory Affairs Professionals Society. “EU Commission Drafts Guidelines on Classifying High-Risk Systems Under the AI Act.” RAPS, 2026. https://www.raps.org/resource/eu-commission-drafts-guidelines-on-classifying-high-risk-systems-under-the-ai-act.html (accessed 2026-07-12).

8. Dicentra. “AI Hallucinations: Why Regulators Are Paying Attention.” Dicentra, 2026. https://dicentra.com/blog/artificial-intelligence/ai-hallucinations-why-regulators-are-paying-attention (accessed 2026-07-12).

9. Council for Responsible Nutrition. “AI in Action: Product Innovation and Compliance in Dietary Supplements.” CRN (Council for Responsible Nutrition), 2025. https://crnusa.org/CRN-Experts-Explain/Akash-Shah-IngredientAI (accessed 2026-07-12).

10. European Union. “Regulation (EU) 2024/1689 of the European Parliament and of the Council laying down harmonised rules on artificial intelligence (Artificial Intelligence Act).” EUR-Lex, 2024. https://eur-lex.europa.eu/eli/reg/2024/1689/oj (accessed 2026-07-12).

11. European Union. “Regulation (EU) 2015/2283 on novel foods.” EUR-Lex, 2015. https://eur-lex.europa.eu/eli/reg/2015/2283/oj (accessed 2026-07-12).

12. European Union. “Regulation (EC) No 1924/2006 on nutrition and health claims made on foods.” EUR-Lex, 2006. https://eur-lex.europa.eu/eli/reg/2006/1924/oj (accessed 2026-07-12).

These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease. It is informational only and is not regulatory, legal, or compliance advice, and it is not an endorsement of any tool or vendor. AI capabilities, product features, and regulatory guidance change over time; confirm current requirements against the applicable authorities (FDA, FTC, EFSA, and the EU AI Act, among others) and validate any tool for your specific context of use before relying on it.

Read our article on AI Formulation Tools Reshaping the Nutraceutical Industry in 2026